Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

More affordable pneumonia vaccine can protect more kids

Facts about pneumonia vaccine - January 2020
Facts about pneumonia vaccine - January 2020
Facts about pneumonia vaccine - January 2020
Facts about pneumonia vaccine - January 2020

Read, watch, share

Campaign asking Pfizer & GSK to drop the prices of pneumonia vaccines down to 5$/child Photograph by MSF

When prices are hidden, you can essentially set the price as high as you'd like. No one would know, right? It's absurd, but unfortunately, this is the way pharmaceutical companies set prices for their life-saving pneumonia vaccines.

Press release
Press release |
23 April 2015
Vaccines

MSF kicks off global ████ to reduce the price of ████ to $5 in developing countries

5 min
2013 marked the first time that PCV is being used in South Sudan and one of the first vaccines to be implemented in compliance with the new WHO emergency vaccination recommendations. Photograph by Yann Libessart
Press release
Press release |
26 January 2015
Vaccines

MSF responds to Pfizer announcement of pneumococcal vaccine price reduction

3 min
DESCRIPTION:MSF stunt in Berlin outside the venue of the Gavi replenishment meeting, demanding GSK and Pfizer to reduce their price for the pneumococcal vaccine to $5 per child. The stunt involves world leaders spinning a wheel of chance in which - when it comes to the PCV vaccine - pharma almost always wins. Photograph by Stephanie Pilick
Press release
Press release |
20 January 2015
Vaccines

MSF response to GSK and Pfizer’s statement on the pneumonia vaccine (pneumococcal conjugate vaccine, PCV)

2 min
MSF held the first of three rounds of a mass vaccination campaign in Adjumani district of northern Uganda to protect children from deadly respiratory infections, July 2014. Photograph by Markel Redondo
Press release
Press release |
19 January 2015
Vaccines

MSF calls on GSK and Pfizer to slash pneumo vaccine price to $5 per child for poor countries ahead of donor meeting

5 min
Sudanese refugees began streaming across the border into South Sudan in June 2011 when conflict erupted between the Khartoum government and the rebels of the Sudan People’s Liberation Movement-North (SPLM-N) in Sudan’s South Kordofan State. Photograph by Yann Libessart Photograph by Yann Libessart
Press release
Press release |
08 August 2013
Vaccines
South Sudan

Global vaccination community turns its back on getting new vaccines to refugee children

Press release |
23 April 2013
Intellectual property and trade Vaccines

Global vaccines community must bring price of new vaccines down

Press release |
05 December 2012
Intellectual property and trade Vaccines
Kenya

MSF Urges GAVI to Extend Vaccine Prices to Humanitarian Actors to Help Close Gap of Unvaccinated Children

Press release |
08 November 2012
Vaccines
AfricaNiger

Research results show need to tailor vaccines to improve their impact

  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury